Novel once-daily extended-release tacrolimus versus twice-daily tacrolimus in de novo kidney transplant recipients: Two-year results of phase 3, double-blind, randomized trial

Lionel Rostaing, Suphamai Bunnapradist, Josep M. Grinyó, Kazimierz Ciechanowski, Jason E. Denny, Helio Tedesco Silva, Klemens Budde

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)648-659
Number of pages12
JournalAmerican Journal of Kidney Diseases
Volume67
Issue number4
DOIs
StatePublished - Apr 1 2016
Externally publishedYes

ASJC Scopus Subject Areas

  • Nephrology

Keywords

  • Envarsus
  • Immunosuppression
  • bioavailability
  • biopsy-proven acute rejection
  • efficacy
  • end-stage renal disease (ESRD)
  • extended-release
  • formulation
  • kidney transplantation
  • pill burden
  • randomized controlled trial (RCT)
  • safety
  • tacrolimus
  • transplant recipient
  • treatment failure

Cite this